Migraine is the third most common disease in the world
with an estimated global prevalence of 14.7%
that’s around 1 in 7 people
Drug repurposing to treat migraine
Using the target identification and validation platform, Geneware has identified an approved drug with the ability to interfere with a recently uncovered pain signaling pathway that’s involved in migraine. This follows a similar development path that Viagra and Botox had been repurposed for different indications. This could potentially save millions in cost and years in time to bring a product to market for migraine. Geneware is now in partnership with a pharma company to further develop it.